The Food and Drug Administration Office of Women's Health: Impact of science on regulatory policy

Journal of Women's Health

Volumn 16, Issue 6, 2007, Pages 807-817

  Obias Manno, Dulce ^a   Scott, Pamela E ^a   Kaczmarczyk, Joseph ^a   Miller, Margaret ^a,b   Pinnow, Ellen ^a   Lee Bishop, Lynda ^c   Jones London, Michelle ^d   Chapman, Kennerly ^a   Kallgren, Deborah ^a   Uhl, Kathleen ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIET SUPPLEMENTATION; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; QT PROLONGATION; RESEARCH PRIORITY; REVIEW; SCIENCE; WOMEN'S HEALTH;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BUDGETS; FEMALE; HEALTH POLICY; HUMANS; LEADERSHIP; POLICY MAKING; RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 34547948551     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.0135     Document Type: Review

References (81)

1. Senate report 103-102 July 20, 1993.
2. Update on women and family issues in Congress. Available at www.mith2.umd.edu/WomensStudies/GovernmentPolitics/CaucusUpdates/ Update-vol14no4/headlines Accessed October 22, 2006.
3. Federal Register. Department of Health and Human Services Notice GN #2260. 1994, July 28;59:144.
4. Ten years and Beyond. Available at: www.fda.gov/womens/reports/ report0306.pdf Accessed October 25, 2006.
5. U.S. Food and Drug Administration: OWH Science Program available at www.fda.gov/womens/science.html Accessed October 25, 2006.
6. Wizemann TM, Pardue M-L, eds. Exploring the biological contributions to human health: Does sex matter? Washington, DC: National Academy Press, 2001.
7. Schiebinger L. Women's health and clinical trials J Clin Invest 2003;112:973.
8. Miller MA. Gender-based differences in the toxicity of pharmaceuticals - The Food and Drug Administration's perspective. Int J Toxicol 2001;20:149.
9. Merkatz RB, Temple R, Subel S, Feiden K, Kessler DA. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med 1993;329:292.
10. Merkatz RB, Junod SW. Historical background of changes in FDA policy on the study and evaluation of drugs in women. Acad Med 1994;69:703.
11. U.S. Food and Drug Administration. Guidance for industry: General considerations for the clinical evaluation of drugs, 1977. Available at www.fda.gov/cder/guidance/old034fn.pdf Accessed October 4, 2006.
12. U.S. General Accounting Office. Women's health: FDA needs to ensure more study of gender differences in prescription drug testing, HRD-93-17. October 29, 1992. Available at archive.gao.gov/d35t11/147861.pdf. Accessed April 25, 2006.
13. U.S. Food and Drug Administration. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs, 1993. Available at www.fda.gov/cder/guidance/old036fn.pdf Accessed April 25, 2006.
14. Gender studies in product development: Scientific Issues and Approaches, November 1995. Available at www.fda.gov/womens/gender.html Accessed October 14, 2006.
15. U.S. Food and Drug Administration. The Office of Women's Health scientific research program: Abstracts. Development and expansion of a pilot tracking system for monitoring the barriers to the enrollment of women in clinical trials. Available at www.fda.gov/womens/scienceprogram/report2000/ abstracts.htm#womenclinical Accessed April 26, 2006.
16. Huang S-M, Miller M, Toigo T, et al. Evaluation of drugs in women: Regulatory perspective. In: Legato M, ed. Principles of gender-specific medicine. New York: Elsevier Academic Press, 2004:848.
17. The Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act. 21 CFR 812.
18. FDA Consumer Magazine. September-October 2004. Making an informed decision about breast implants Available at www.fda.gov/fdac/features/2004/ 504_implants.html
19. James SJ, Pogribna M, Miller BJ, Bolon B, Muskhelishvili L. Characterization of cellular response to silicone implants in rats: Implications for foreign body carcinogenesis. Biomaterials 1997;18:667.
20. Abbondanzo SL, Young VL, Wei MQ, Miller FW. Silicone gel-filled breast and testicular implant capsules: A histologic and immunophenotypic study. Mod Pathol 1999;12:706.
21. O'Hanlon TP, Lawless OJ, Katzin WE, Feng LJ, Miller FW. Restricted and shared patterns of TCR beta-chain gene expression in silicone breast implant capsules and remote sites of tissue inflammation. J Autoimmun 2000;14:283.
22. Brown SL, Middleton MS, Berg WA, Soo MS, Pennello G. Prevalence of rupture of silicone gel breast implants revealed on MR imaging in a population of women in Birmingham, Alabama. Am J Roentgenol 2000;175:1057.
23. Brown SL, Pennello G, Berg WA, Soo MS, Middleton MS. Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. J Rheumatol 2001;28:996.
24. Brown SL, Pennello G. Replacement surgery and silicone gel breast implant rupture: Self-report by women after mammoplasty. J Womens Health Gend Based Med 2002;11:255.
25. U.S. Food and Drug Administration. Guidance for saline, silicone gel, and alternative breast implants; Guidance for industry and FDA. February 2003. Available at www.fda.gov/cdrh/ode/guidance/1354.pdf Accessed May 31, 2006.
26. U.S. Food and Drug Administration. The Office of Women's Health Scientific Program: Appendix I. Women in clinical trials. Available at www.fda.gov/womens/scienceprogram/report2000/appendix.htm Accessed October 14, 2006.
27. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005;26:119.
28. Moss AJ. The QT interval and torsade de pointes. Drug Saf 1999;21(Suppl 1):5.
29. Chauhan VS, Krahn AD, Walker BD, Kelin GJ, Skanes AC, Yee R. Sex differences in QTc interval and QT dispersion: Dynamics during exercise and recovery in healthy subjects. Am Heart J 2002;144:858.
30. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690.
31. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000;67:413.
32. Rodriguez I, Kilborn MJ, Liu XK, Pezzollo JZ, Woosley RL Drug-induced QT prolongation in women during the menstrual cycle JAMA 2001;285:1322.
33. Data mining AERS. Available at www.fda.gov/ohrms/dockets/ac/05/slides/ 2005-4143S1_07_McCloskey.ppt Accessed October 25, 2006.
34. Szarfman A, Machado SG, O'Neill RT Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002;25:381.
35. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: A tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003;12:517.
36. U.S. Food and Drug Administration. Poster abstracts. Gender-related "higher-than-expected" drug-event combinations in spontaneous adverse drug event reports, CDER, FDA 2000 FDA Science Forum. Available at vm.cfsan.fda.gov/~frf/forum00/abst00ct.htm Accessed April 26, 2006.
37. Heist EK, Ruskin JN. Drug-induced proarrhythmia and use of QTc-prolonging agents: Clues for clinicians. Heart Rhythm 2005;2(Suppl 2):S1.
38. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698.
39. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med 2005;165:1363.
40. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: The evolving role of pharmacogenetics. Heart Rhythm 2005;2(Suppl 2):S30.
41. U.S. General Accounting Office. Drugs withdrawn from market. Drug safety: Most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R, 2001. Available at www.gao.gov/new. items/d01286r.pdf Accessed April 25, 2006.
42. FDA Medwatch. 2002 Safety alert (Ziprasidone HCL) Available at www.fda.gov/medwatch/SAFETY/2002/geodon.htm Accessed April 27, 2006.
43. U.S. Food and Drug Administration. Important drug warning: Inapsine (Droperidol). Available at www.fda.gov/medwatch/SAFETY/2001/inapsine.htm Accessed April 27, 2006.
44. U.S. Food and Drug Administration. Dear healthcare professional (Fluothane), 2000. Available at www.fda. gov/medwatch/safety/2000/fluoth. htm Accessed April 27, 2006.
45. Shah RR. Drug-induced prolongation of the QT interval: Regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundam Clin Pharmacol 2002;16:147.
46. U.S. Food and Drug Administration. Safety pharmacologic studies for assessing the potential for delayed ventricular repolarization (Qt interval prolongation by human pharmaceuticals). ICH draft S7B, 2002. Available at www.fda.gov/ohrms/dockets/98fr/02d-0232-gdl0001-vol1.PDF Accessed April 25, 2006.
47. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and non-torsadogenic drugs. J Pharmacol Exp Ther 2005;316:1098.
48. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinicalQT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32.
49. Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004;66:33.
50. Kroll CR, Gettes LS. T wave alternans and torsades de pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol 2002;13:936.
51. U.S. Food and Drug Administration. Guidance for industry: S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals, 2005. Available at www.fda.gov/cder/ guidance/6885fnl.htm Accessed April 25, 2006.
52. Sica DA, Wood M, Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: Recent considerations. Congest Heart Fail 2005;11:163.
53. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 1994;15:619.
54. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41:329.
55. Chen ML. Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther 2005;78:322.
56. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet 2005;44:989.
57. Uhl K, Miller MA, Kennedy DL. Complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials. J Womens Health 2004;13:743.
58. FDA regulated products and pregnant women, 1994. Available at www.fda.gov/bbs/topics/ANSWERS/ANS00601.html Accessed October 25, 2006.
59. Hebert MF, Carr DB, Anderson GD, et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 2005;45:25.
60. OWH Science Program: Pregnancy initiatives. Available at www.fda.gov/womens/science.html#pregnancy Accessed May 15, 2006.
61. Pharmacokinetics of labetalol in pregnancy. Pharmacotherapy 2005;25:1519. Available at www.pharmacotherapy.org/pdf/free/Pharm2510_ACCP-Abstracts.pdf
62. U.S. Food and Drug Administration. Guidance for industry on pharmacokinetics in pregnancy-study design, data analysis, and impact on dosing and labeling, 2004. Available at www.fda.gov/cder/guidance/5917dft.pdf Accessed April 25, 2006.
63. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35.
64. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and panax ginseng. J Clin Pharmacol 2003;43:643.
65. Mahady GB, Parrot J, Lee C, Yun G S, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10:65.
66. Hall SD, Wang C, Huang SM, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol 2003;74:525.
67. Upchurch DM, Chyu L. Use of complementary and alternative medicine among American women. Womens Health Issues 2005;15:5.
68. U.S. Food and Drug Administration. Guidance for industry: Labeling for combined oral contraceptives, 2004. Available at www.fda.gov/cder/guidance/ 5197dft.pdf Accessed April 25, 2006.
69. U.S. Food and Drug Administration. Guidance for industry: Non-contraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms, 2005. Available at www.fda.gov/cder/guidance/6932dft.pdf. Accessed May 3, 2006.
70. Physicians' desk reference: Levonorgestrel and ethinyl estradiol. Physicians' Desk Reference, edition 59. Montvale, NJ. Thompson PDR, 2005, pg. 3311.
71. Gorski JC, Huang M-S, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004;75:89.
72. Huang S-M, Temple R, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food onteractions - Labeling implications. In: Lam F, Huang S-M, Hall S, eds. Drug-herb interactions - Scientific and regulatory challenge. New York: Marcel Dekker, 2006.
73. Rier S, Foster WG. Environmental dioxins and endometriosis. Semin Reprod Med 2003;21:145.
74. Heilier JF, Nackers F, Verougstraete V, Tonglet R, Lison D, Donnez J. Increased dioxin-like compounds in the serum of women with peritoneal endometriosis and deep endometriotic (adenomyotic) nodules. Fertil Steril 2005;84:305.
75. Birnbaum LS, Cummings AM. Dioxins and endometriosis: A plausible hypothesis. Environ Health Perspect 2002;110:15.
76. Archer JC, Mabry-Smith R, Shojaee S, Threet J, Eckert JJ, Litman VE. Dioxin and furan levels found in tampons. J Womens Health 2005;14:311.
77. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Statistician 1999;53:177.
78. Obias-Manno D, Scott P, Kaczmarczyk J, Pinnow E, Uhl K, OWH. The Office of Women's Health: Impact of research program [abstract] K-29. 206 FDA Science Forum. Available at www.cfsan.fda.gov/~frf/forum06/abs06ct.html#K Accessed April 28, 2006.
79. The critical path to new medical products. Available at www.fda.gov/oc/initiatives/criticalpath/ Accessed October 18, 2006.
80. Shuren J. Workshop on sex differences and the Food and Drug Administration Critical Path Initiative Fed Reg 2006;71:59511. Available at www.fda.gov/OHRMS/DOCKETS/98fr/E6-16605.pdf
81. U.S. FDA. FDA and Duke Clinical Research Institute form partnership to collaborate on cardiac safety virtual. Available at www.fda.gov/bbs/topics/ news/2006/new01467.html